Pair Name	Ginsenoside Rh2, Anti-PD-L1 antibody
Partner Name	Ginsenoside Rh2
Disease Info	[ICD-11: 2A00-2F9Z]	Solid tumour or cancer		Investigative
Biological Phenomena	Induction-->Immunomodulatory
Gene Regulation	Up-regulation	Expression	IRF1	hsa3659
	Up-regulation	Phosphorylation	IRF3	hsa3661
	Up-regulation	Phosphorylation	STAT1	hsa6772
	Up-regulation	Phosphorylation	TBK1	hsa29110
In Vitro Model	MC-38	Mouse colon adenocarcinoma	Mus musculus (Mouse)	CVCL_B288
	CT26	Mouse colon adenocarcinoma	Mus musculus (Mouse)	CVCL_7254
	4T1	Malignant neoplasms of the mouse mammary gland	Mus musculus (Mouse)	CVCL_0125
In Vivo Model	The right flank of C57BL/6 mice were received with the subcutaneous injection of 1×10⁶ MC38 cells,2.5×105 4T1 cells or 1×10⁶ CT26 cells were subcutaneously injected into the right flank of BALB/c mice.
Result	These findings demonstrated that Rh2 potentiated the anti-cancer effect of PD-L1 blockade via promoting the T cells infiltration and activation, which shed a new light on the combination strategy to enhance anti-PD-L1 immunotherapy by using natural product Rh2.

Pair Name	All-trans retinoic acid, Anti-PD-L1 antibody
Partner Name	All-trans-retinoic acid
Disease Info	[ICD-11: 2C77]	Cervical cancer		Investigative
Gene Regulation	Down-regulation	Expression	ARG1	hsa383
	Down-regulation	Expression	CD274	hsa29126
	Down-regulation	Expression	CYBB	hsa1536
	Up-regulation	Expression	IFNG	hsa3458
	Down-regulation	Expression	NOS2	hsa4843
	Up-regulation	Expression	TNF	hsa7124
In Vitro Model	HeLa	Human papillomavirus-related cervical adenocarcinoma	Homo sapiens (Human)	CVCL_0030
	C-33 A	Human papillomavirus-independent cervical squamous cell carcinoma	Homo sapiens (Human)	CVCL_1094
	U14	Cervical carcinoma	Mus musculus (Mouse)	CVCL_9U56
In Vivo Model	Mouse cervical cancer U14 cells were prepared as mentioned above and a total of 1×10⁶ U14 cells were subcutaneously injected into the abdominal cavity of the mice for a week.
Result	Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer.